62,178 Progyny, Inc. $PGNY Shares Purchased by William Blair Investment Management LLC

William Blair Investment Management LLC increased its position in Progyny, Inc. (NASDAQ:PGNY – Free Report) by 10.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 645,130 shares of the company’s stock after acquiring an additional 62,178 shares during the quarter. William Blair Investment Management LLC owned about 0.84% of Progyny worth $16,251,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of PGNY. Public Employees Retirement System of Ohio bought a new stake in Progyny during the 2nd quarter worth approximately $29,000. Nykredit A S purchased a new stake in Progyny in the 2nd quarter worth approximately $38,000. IFP Advisors Inc boosted its holdings in Progyny by 376.0% in the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock valued at $57,000 after purchasing an additional 1,549 shares during the period. Toth Financial Advisory Corp bought a new position in Progyny in the 2nd quarter valued at $65,000. Finally, Integrated Wealth Concepts LLC bought a new position in Progyny in the 2nd quarter valued at $74,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on PGNY shares. Citigroup restated a “market outperform” rating on shares of Progyny in a research report on Thursday, November 5th. Canaccord Genuity Group set a $35.00 price objective on Progyny in a research report on Friday, August 7th. Leerink Partners increased their price objective on Progyny from $37.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th. Truist Financial lifted their price objective on Progyny from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Finally, Cantor Fitzgerald boosted their target price on Progyny from $31.00 to $35.00 and gave the stock an “overweight” rating in a research report on Thursday, November 5th. Eleven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Progyny currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.33.

Get Our Latest Stock Report on PGNY

Progyny Stock Performance

PGNY stock opened at $36.18 on Monday. The company’s 50 day moving average is $28.48 and its 200 day moving average is $24.87. The stock has a market cap of $2.66 billion, a price-to-earnings ratio of 33.19, a price-to-earnings-growth ratio of 1.66 and a beta of 0.97. Progyny, Inc. has a 1-year low of $16.10 and a 1-year high of $37.15.

Progyny (NASDAQ:PGNY – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.21. Progyny had a net margin of 6.80% and a return on equity of 19.82%. The business had revenue of $341.25 million for the quarter, compared to the consensus estimate of $340.76 million. During the same period last year, the firm posted $0.15 earnings per share. Progyny’s quarterly revenue was up 8.9% on a year-over-year basis. As a group, sell-side analysts forecast that Progyny, Inc. will post 1.43 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Chairman David Schlanger sold 161,208 shares of the stock in a transaction on Monday, November 9th. The shares were sold at an average price of $35.73, for a total value of $5,759,961.84. Following the transaction, the chairman owned 238,462 shares of the company’s stock, valued at $8,520,247.26. This represents a 40.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Peter Anevski sold 236,630 shares of the firm’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $35.84, for a total transaction of $8,480,819.20. Following the sale, the chief executive officer owned 710,972 shares in the company, valued at approximately $25,481,236.48. This trade represents a 24.97% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 630,072 shares of company stock worth $22,363,084. 9.90% of the stock is owned by corporate insiders.

Progyny Profile

(Free Report)

Progyny, Inc. provides fertility and family-building benefits to employers and their employees. Its services are designed to help members navigate care options, access fertility specialists and receive support throughout treatment. The company’s offerings include coverage for treatments such as in vitro fertilization and egg freezing, along with fertility medications through its pharmacy benefit. Progyny also supports other family-building paths, including adoption and surrogacy, depending on the plan selected by an employer.

Featured Stories

Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY – Free Report).

Institutional Ownership by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.